Blood Cancer DiscoveryCancer BiologyPeer-reviewed journal article
Pyjacker identifies enhancer hijacking events in acute myeloid leukemia including MNX1 activation via deletion 7q
Etienne SollieriD, Anna RiedeliD, Umut H. ToprakiD, Justyna A. WierzbińskaiD, Dieter WeichenhaniD, Jan Philipp SchmidiD, Mariam HakobyaniD, Aurore TouzartiD, Ekaterina JahniD, Binje VickiD, Fiona Brown-BurkeiD, Katherine A. KellyiD, Simge KelekçiiD, Anastasija PejkovskaiD, Ashish GoyaliD, Marion BähriD, Kersten BreueriD, Mei-Ju May CheniD, Maria Llamazares PradaiD, Mark HartmanniD, Maximilian SchönungiD, Nádia CorreiaiD, Andreas TrumppiD, Yomn AbdullahiD, Ursula KlingmülleriD, , Christoph PlassiD
Abstract
Acute myeloid leukemia with complex karyotype (ckAML) is characterized by high genomic complexity, including frequent TP53 mutations and chromothripsis. We hypothesized that the numerous genomic rearrangements could reposition active enhancers near proto-oncogenes, leading to their aberrant expression. We developed pyjacker, a computational tool for the detection of enhancer hijacking events, and applied it to a cohort of 39 ckAML samples. Pyjacker identified motor neuron and pancreas homeobox 1 (MNX1), a gene aberrantly expressed in 1.4% of AML patients, often as a result of del(7)(q22q36) associated with hijacking of a CDK6 enhancer. MNX1-activated cases show significant co-occurrence with BCOR mutations and a gene signature shared with t(7;12)(q36;p13) pediatric AML. We demonstrated that MNX1 is a dependency gene, as its knockdown in a xenograft model reduces leukemia cell fitness. In conclusion, enhancer hijacking is a frequent mechanism for oncogene activation in AML. Statement of significanceThis study examines the consequences of structural alterations and demonstrates that proto-oncogene activation by enhancer hijacking is an overlooked pathomechanism in AML. MNX1 overexpression demonstrates that deletions on chromosome 7q can not only lead to haploinsufficiency, but also to activation of oncogenes by enhancer hijacking, providing a novel leukemogenic mechanism.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- Citations
- 8
- FWCI
- 5.73
- Field percentile
- top 4%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13)
D. Weichenhan, A. Riedel, … C. Plass·bioRxiv·Sep 13, 2023
- Integrative enhancer discovery identifies functional enhancer dependencies in pediatric acute myeloid leukemia
Leah Schüler, Robert E. Winkler, … Jan‐Henning Klusmann·bioRxiv·Aug 21, 2026
- Aberrant MNX1 Expression Associated with t(7;12)(q36;p13) Pediatric Acute Myeloid 1 Leukemia Induces the Disease Through Altering Histone Methylation
A. Waraky, A. Ostlund, … L. Palmqvist·bioRxiv·Jun 10, 2022
- Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia
T. P. Braun, M. Okhovat, … J. E. Maxson·bioRxiv·May 15, 2019
- Mutational synergy coordinately remodels chromatin accessibility, enhancer landscape and 3-Dimensional DNA topology to alter gene expression during leukemia induction
H. Yun, S. Vohra, … B. J. P. Huntly·bioRxiv·Mar 20, 2020
- Acute Myeloid Leukemia with deletion 5q is an epigenetically distinct subgroup defined by heterozygous loss of KDM3B
Katherine A. Kelly, Linda Welte, … Christoph Plass·bioRxiv·Nov 13, 2024